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Abstract: Purpose
The prevalence and the etiopathogenesis of thyroid dysfunctions in Klinefelter
syndrome (KS) are still unclear. The primary aim of this study was to evaluate the
pathogenetic role of hypogonadism in the thyroid disorders described in KS, with the
scope to distinguish between genetic alterations or hormonal involvement. Therefore,
we evaluated thyroid function in KS and in non-KS hypogonadal patients.
Methods
This is a case-control multicentre study from KING group: Endocrinology clinics in
university-affiliated medical centres. One hundred seventy four KS, and sixty-two non-
KS hypogonadal men were enrolled. The primary outcome was the prevalence of
thyroid diseases in KS and in non-KS. Changes in hormonal parameters were
evaluated. Exclusion criterion was secondary hypothyroidism. Analyses were
performed using Student’s t test. Mann-Whitney test and chi-square test.
Results
FT4 was significantly lower in KS vs non-KS. KS and non-KS presented similar TSH
and testosterone levels. Hashimoto’s thyroiditis (HT) was diagnosed in 7% of KS. Five
KS developed hypothyroidism. The ratio FT3/FT4 was similar in both groups. TSH
index was 1.9 in KS and 2.3 in non-KS. Adjustment for differences in age, sample size
and concomitant disease in multivariate models did not alter the results.
Conclusions
We demonstrated in KS no etiopathogenic link to hypogonadism or change in the set
point of thyrotrophic control in the altered FT4 production. These results suggest
possible deiodinase impairment. The prevalence of HT in KS was similar to normal
male population, showing absence of increased risk of HT associated with the XXY
karyotype.
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Response to Reviewers: Comments and answers
Reviewer #1: In this paper titled "Thyroid function in Klinefelter syndrome (KS): a
multicenter study from KING group", the authors compared thyroid function in a group
of patients with Klinefelter with a group of hypogonadal patients. The aim of the study
is to clarify the prevalence and etiology of hypothyroidism in KS patients. Thyroid
function was studied using serum hormonal and antibody concentration. The authors
conclude that there is no etiopathogenic link between KS and hypothyroidism, and that
the KS patients present an impaired production of T4 by the thyroid gland, with an
adaptive type II deiodinase activity that allows a normal peripheral circulating amount
of FT3 and normal TSH levels.
In the abstract, page 2 line 19 (it is in line 9): the number of KS patients (174) does not
coincide with the number in table 1 (176). The correct number of KS patients is 174.
This has been corrected here and throughout the manuscript.
Page 4, lane 2: Authors should check that the number of KS patients declared (174) is
correct. The correct number of KS patients is 174. This has been corrected here and
throughout the manuscript.
The same check should be made at every point where this number is being reported
[page 4 line 19 (this in in line 9) and table 1]. The correct number of KS patients is 174.
This has been corrected here and throughout the manuscript.
Page 7 line 17 The authors should consider the following review: Mol Cell Endocrinol.
2018 May 15;467:49-59. doi: 10.1016/j.mce.2017.11.006 as a introduction to the
behavioral impact, if any, of the slight TH derangements here found (see also:
Endocrine. 2015 Jun;49(2):333-8. doi: 10.1007/s12020-014-0520-7. and Mol Hum
Reprod. 2010 Jun;16(6):418-24. doi: 10.1093/molehr/gaq022.) highlighting that the
ejaculatory control has never been studied in KS.
We considered these article and, as requested, included them in the discussion.
Authors may consider to delete the figure 1 that is not significant and to replace it with
a figure of FT4 levels, which are significantly different between the two groups
analyzed.
We modified the figures (Figure 1, 2 and 3), as requested.
Reviewer #2: The manuscript by Dr Balercia et al entitled "Thyroid function in
Klinefelter syndrome: a multicenter study from KING group" investigates the thyroid
function in a relevant number of KS patients. This research finds that the prevalence of
thyroid autoimmune disorders in KS patients is not different from the general
population and that KS patients show mildly reduced FT4 levels compared to another
hypogonadic control group. This is a multicentric study, conducted by specialists who
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
are experts of KS. These findings are somehow confirmatory of previous studies.
Major criticisms
1)    It is unclear how the work is designed to distinguish between "genetic alterations
or hormonal involvement". This sentence should be rephrased. The sentence was
reworded to enhance its clarity.
2)    Taking into account that FT4 measurement is so critical for the results of this work,
the percentage of the different assays and manufacturer employed to measure FT4
should be indicated in the methods section. We reported the coefficient of variation for
FT4 assay in Methods (Daniela per favore vedi il testo).
3)    If “an altered T4 production by the thyroid gland” is present and TSH levels are not
increased (compared to controls) this suggests a different set point of the thyroid axis
in the two experimental groups. This hypothesis is more plausible than alterations
based only on increased D2 activity.
We agree with the Reviewer. Therefore, and we removed all the discussion on
deiodinase from the Abstract and the Discussion, considering it as a possible starting
point for further studies.
4)    To interpret adequately thyroid function data, iodine intake and urinary iodine
should have been measured. This is an important limitation of the study. We included
these comments among possible future research development in KS patients.
5)    From the results section it is unclear if the prevalence of TH, in the two
experimental groups, is different or not. Since this is not the case, the data can be
reported in table 1. We reported the prevalence of TH in Table 1.
6)    The involvement of D2 activation in this context is not enough supported by the
results or by previous findings. For this reason, this speculation, should be removed
from the abstract and discussion.
We agree with the Reviewer. Therefore, and we removed all the discussion on
deiodinase from the Abstract and the Discussion, considering it as a possible starting
point for further studies. See also Q3.
Suggested Reviewers: Anders Juul
anders.juul@regionh.dk
International expert of Klinefelter syndrome
Stefan Schlatt
stefan.schlatt@ukmuenster.de
An international expert of Klinefelter syndrome
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Abstract 1 
Purpose: The prevalence and the etiopathogenesis of thyroid dysfunctions in Klinefelter syndrome 2 
(KS) are still unclear. The primary aim of this study was to evaluate the pathogenetic role of 3 
hypogonadism in the thyroid disorders described in KS, with the scope to distinguish between 4 
patients with KS and hypogonadism due to other causes (Kallmann syndrome, idiopathic 5 
hypogonadotropic hypogonadism, iatrogenic hypogonadism and acquired hypogonadotropic 6 
hypogonadism after surgical removal of pituitary adenomas) called non-KS. Therefore, we 7 
evaluated thyroid function in KS and in non-KS hypogonadal patients.  8 
Methods: This is a case-control multicentre study from KING group: Endocrinology clinics in 9 
university-affiliated medical centres. One hundred seventy four KS, and sixty-two non-KS 10 
hypogonadal men were enrolled. The primary outcome was the prevalence of thyroid diseases in 11 
KS and in non-KS. Changes in hormonal parameters were evaluated. Exclusion criterion was 12 
secondary hypothyroidism. Analyses were performed using Student’s t test. Mann-Whitney test and 13 
chi-square test. 14 
Results: FT4 was significantly lower in KS vs non-KS. KS and non-KS presented similar TSH and 15 
testosterone levels. Hashimoto’s thyroiditis (HT) was diagnosed in 7% of KS. Five KS developed 16 
hypothyroidism. The ratio FT3/FT4 was similar in both groups. TSH index was 1.9 in KS and 2.3 in 17 
non-KS.  Adjustment for differences in age, sample size and concomitant disease in multivariate 18 
models did not alter the results. 19 
Conclusions: We demonstrated in KS no etiopathogenic link to hypogonadism or change in the set 20 
point of thyrotrophic control in the altered FT4 production. The prevalence of HT in KS was similar 21 
to normal male population, showing absence of increased risk of HT associated with the XXY 22 
karyotype. 23 
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 1 
Introduction 2 
Klinefelter Syndrome (KS) is the most frequent observed sex chromosomal anomaly, with an 3 
estimated frequency of 1:500 to 1:1000 men (1). The classic form of KS, which is present in the 80–4 
90 % of the cases, is defined by a 47,XXY karyotype, low serum testosterone (T) coupled with 5 
elevated gonadotropins, small and firm testes, azoospermia, and tall stature. The clinical 6 
presentation of KS syndrome is widely heterogeneous. Only about one in 10 males with KS is 7 
diagnosed before puberty and 25-50% in adult age, often during infertility investigation. KS is 8 
associated with several clinical conditions coming from both the genetic abnormalities, and 9 
hypogonadism. KS patients present several comorbidities including cardiovascular diseases, 10 
osteoporosis, diabetes mellitus, and metabolic syndrome, leg ulcers, mostly related to 11 
hypogonadism (2-5). Consequently, KS males need lifelong testosterone replacement treatment.  12 
Yet, the therapy does not counteract or prevent all comorbidities. It is still unclear whether the extra 13 
chromosome X adds an extra testosterone-independent feature to the complexity of KS 14 
comorbidities.  Thus, the relationship between clinical phenotype, endocrine dysfunction, KS 15 
comorbidities and genetic background needs further investigations (1). Various thyroid 16 
abnormalities were described, mostly in old studies based on few participants, the most common 17 
being a low response in serum TSH to a TRH stimulation test (6,7). KS had a general shift toward 18 
lower values in distribution of serum FT4 with no compensatory increase in serum TSH (8). The 19 
most likely mechanism suggested is a decrease or change in set point of thyrotrophic control of 20 
thyroid function (8). Recently a study demonstrated that pubertal KS patients have significantly 21 
lower FT3 serum levels than healthy age-matched boys, whereas TSH and FT4 are in the normal 22 
reference range (9). Furthermore, some authors have recently analysed KS comorbidities using data 23 
from the Danish National Patient Registry (10). They searched for differentially expressed genes in 24 
peripheral blood and found several expression signatures that correlated with KS status either 25 
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  4 
positively or negatively. Genes involved in ‘abnormal thyroid hormone metabolism’ were 1 
upregulated (10).   2 
To better clarify the prevalence of thyroid diseases and the role of 47XXY as well as the 3 
hypogonadism in thyroid dysregulation, we studied thyroid function in one hundred seventy four 4 
patients with KS compared with non-KS hypogonadal men. 5 
 6 
Subjects and Methods 7 
Patient population 8 
We performed a multicentre case control-study, involving the national network of academic or 9 
general hospitals named KING (Klinefelter ItaliaN Group). The entire cohort consisted of one 10 
hundred seventy four consecutive KS subjects, and sixty-two age-matched non-KS hypogonadal 11 
men recruited among those regularly attending KING centres since 2015. Inclusion criteria were: i) 12 
a verified KS karyotype (47, XXY); ii) a written informed consent. Patients underwent a complete 13 
medical and family history evaluation. We examined thyroid function, and thyroid antibodies (Ab). 14 
Subjects, who had elevated plasma TPOAb and TgAb above 350 IU/ml, and thyroid parenchyma 15 
heterogeneity with reduced echogenicity, were considered as Hashimoto’s thyroiditis (HT) patients. 16 
Five KS patients were already under l-thyroxine replacement therapy.  17 
Collection of samples  18 
Venous blood (2 mL) from participants was collected by blood banks of the hospitals of the KING 19 
centres during the same period of KS and non-KS patients’ recruitment.  Samples, blind of 20 
identification, treatment or placebo group, were immediately sent for analysis of TSH, FT4, FT3, 21 
TPOAb and TgAb and total testosterone to the laboratory facility in each hospital institution of the 22 
KING groups. The measurements were done on the same day in primary tubes, after blood 23 
centrifugation at 3200 RPM for 15 min.  24 
Biochemical data 25 
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As we recruited patients regularly attending KING centres, different methods have been used. In the 1 
majority of the cases, serum TSH, FT4, FT3 concentrations were measured by chemiluminescent 2 
immunometric assay (Roche Diagnostics GmbH, Mannheim, Germany). The coefficient of 3 
variation was 5.4% for the FT4 assay. The manufacturer's reference limits are TSH (0.35–4 
5.5 mIU/L), FT4 (10.2–31 pmol/L), and FT3 (3.5–6.5 pmol/L). Detection limit for TSH is 0.005 5 
μIU/mL, functional sensitivity 0.014 μIU/mL. Thyroid function alteration was classified according 6 
to the American Thyroid Association guidelines (11, 12).  Clinically overt hyperthyroidism, 7 
undetectable to less than 0.1mIU/L TSH, more than normal range FT3, and FT4; subclinical 8 
hyperthyroidism, undetectable to less than 0.1 mIU/L TSH and FT3 and FT4 in the normal range 9 
without exogenous T4 intake; clinically overt hypothyroidism, TSH above the upper limit of the 10 
normal range (5mIU/L in our assay) and FT4 below 10.2 pmol/L; and subclinical hypothyroidism, 11 
TSH above the upper limit of the normal range and FT4 in the normal range  (11,12). Total 12 
testosterone was measured by immunoassay using a commercial Kit, automated immunoassays 13 
(DiaSorin Liaison, Saluggia, VC, Italy). 14 
Exclusion criteria 15 
KS patients with mosaic forms of chromosomal aneuploidy or any other structural or numerical 16 
karyotype anomaly, with AZF microdeletions, were excluded. Moreover, exclusion criterion in non-17 
KS control group was also secondary hypothyroidism defined as undetectable to less than 0.1 18 
mIU/L TSH, FT4, and FT3 in the lower range without exogenous T4 intake. Subjects with 19 
clinically overt thyroid dysfunction, or personal or family history of thyroid disease were excluded 20 
from the control sample, which was, therefore, a population of clinically normothyroidal 21 
individuals.  22 
Statistical analysis 23 
Data were tabulated on a spreadsheet and analysed with SPSS statistics 17 software. We calculated 24 
mean and standard deviation for continuous variables.  25 
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Analyses were performed using Student’s t test. TSH and testosterone were analysed using Mann-1 
Whitney test and, for TPO antibodies chi-square test analysis was performed. 2 
All analysis was two-sided and p values minor 0.05 were considered statistically significant.  3 
 4 
This study was approved by “Comitato Etico Seconda Università degli studi di Napoli- Azienda 5 
Ospedaliera Universitaria SUN-AORN Ospedale dei Colli”  n 1489, 26.10.2015 to DP. 6 
 7 
Results 8 
Demographic characteristics of the study groups  9 
The mean age at study entry was 40.6 ± 1 (mean ± SD; range, 16–59) and 40.0 ± 2.4 (mean ± SD; 10 
range, 16–71) years in KS and in non-KS respectively.  The non-KS group was composed by thirty-11 
three Kallmann syndrome patients, seventeen patients with idiopathic hypogonadotropic 12 
hypogonadism, four patients were affected by iatrogenic hypogonadism, and eight by acquired 13 
hypogonadotropic hypogonadism after surgical removal of pituitary adenomas (table 2). The 14 
comparison between KS and non-KS group allowed evaluating the impact of the hypogonadal 15 
condition and the genetic origin of thyroid function alterations in KS. All the subjects were under 16 
testosterone replacement treatment. T levels were similar in both KS (324±69 ng/dl) and non-KS 17 
(284.7±36 ng/dl), and in both groups at the lower end of the normal range. 18 
Hashimoto’s thyroiditis in KS vs. non-KS patients 19 
In KS group 7% of the patients showed TPOAb positivity, while 4% out of sixty-two hypogonadal 20 
non-KS group had HT (Table 1). Five KS with HT were diagnosed with hypothyroidism and treated 21 
with L-Thyroxine substitutive therapy.  22 
Hypothalamic–pituitary–thyroid axis dysregulation in KS 23 
Serum FT4 was significantly lower in men with KS versus non-KS [mean (SD): 10.69 (0.2) vs. 11.7 24 
(0.4) pg/ml; p < 0.006] (Table 1). The FT3/FT4 ratio was similar in KS and in non-KS group (0.32 25 
vs. 0.29, p<0.06) (Figure 2). Nevertheless, KS and non-KS patients showed similar TSH and total T 26 
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levels [TSH: mean (SD): 1.61 (0.87) vs. 1.75 (1.2) p= 0.1; testosterone mean (SD): 324 (69) vs. 284 1 
(36) ng/dl respectively p = 0.2] (Table 1). We calculated TSH Index, an accurate estimation of the 2 
pituitary dysfunction severity in patients with hypopituitarism  (14), that was not statistically 3 
different between   KS compared to non-KS (1.9 vs. 2.1) (Figure 3). Adjustment for differences in 4 
age, sample size and concomitant disease in multivariate models did no alter the results. 5 
 6 
Discussion 7 
The etiopathogenesis of thyroid dysfunction in KS is still under debate. Here we show lower FT4 in 8 
KS, with no changes in FT3 and TSH levels. We have not found a higher prevalence of HT in KS. 9 
The cross talk between thyroid and gonadal hormones is well known. Thyroid hormone regulation 10 
of sex steroid synthesis and action in both the brain and gonads are important for gonad 11 
development and brain sexual differentiation (15, 16). Thyroid transcription factor-1, a homeobox 12 
gene that regulates the transcriptional activity of thyroid-specific genes in thyroid follicular cells, 13 
occupies a central position within gene networks involved in the hypothalamic control of GnRH 14 
production (17). The effects of thyroid hormones in men and their correlations with sexual 15 
behaviour are not yet clear even though several studies show an association between thyroid 16 
diseases and altered sexual function (hypoactive sexual desire disorder, premature and delayed 17 
ejaculation, and erectile dysfunction) (18). KS patients have sexual dysfunctions not specifically 18 
associated with the syndrome but related to hypogonadism (19) although the ejaculatory control in 19 
this category of patients has not yet been studied. 20 
To elucidate if the thyroid dysfunction in KS is related to the peculiarity of 47XXY condition 21 
and/or to T deficiency status, we analysed the occurrence of thyroid diseases in KS and in non-KS 22 
hypogonadal men. We have utilized data from a national multicentre study, to overcome the main 23 
problem arising from KS studies, the small sample size, that makes difficult to draw strong clinical 24 
conclusions. We confirm that males with KS have a shift toward lower values in distribution of 25 
serum FT4 (8). In particular, we have found a significant reduction of FT4 level in KS compared to 26 
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non-KS, with no statistical differences in TSH and FT3 levels. To verify the hypothesis of an 1 
altered set point of thyrotrophic control of thyroid function in KS (8), we have performed TSH 2 
index calculation. TSH index is an “FT4-adjusted TSH” that corrects for any physiological TSH 3 
suppression, to provide a true estimate of pituitary thyrotrophic function and any pathological 4 
pituitary suppression (14). TSH index was not statistically different in KS and non-KS, suggesting 5 
an adequate hypothalamic-pituitary-thyroid axis control. We could speculate that, since in healthy 6 
and iodine-sufficient individuals, the majority of thyroid hormone produced is T4, synthesized 7 
exclusively by the thyroid gland, with a smaller amount (~20%) of T3, which is produced by the 8 
thyroid and in peripheral tissues via deiodination of circulating T4, KS patients could have an 9 
altered T4 production by the thyroid gland. The novel approach with the comparison of FT4 levels 10 
between KS and non-KS patients give us the opportunity to clarify that T deficit, independently of 11 
when it started, cannot be considered as a causal determinant in the pathophysiology of this 12 
condition. Metabolic syndrome and insulin resistance are specific features of KS (1-3, 20-22) and 13 
FT3/FT4 ratio has a better predictive power for metabolic syndrome than TSH (23). We found 14 
comparable FT3/FT4 ratio both in KS and in non-KS, suggesting a similar predisposition to 15 
increased risk of metabolic syndrome parameters and insulin resistance. Then we took the 16 
opportunity to study the prevalence of Hashimoto’s thyroiditis (HT) among KS that resulted to be 17 
7.0%. The prevalence of HT in KS was similar to that reported in healthy male volunteers in the 18 
Pescopagano survey (24,25). In fact, in this comprehensive study of thyroid disease in Italy 17.3 % 19 
of women and 7.0 % of male were affected by HT (24,25).  The X chromosome contains the largest 20 
number of immune-related genes of the whole human genome (26). Skewed X chromosome 21 
inactivation has been considered one of the key factors that influence the female predisposition to 22 
autoimmunity (27). Laboratory studies have shown high levels of autoantibodies to the thyroid 23 
gland among people with KS (28). An English national cohort study of people with KS, found 24 
significantly increased risks of several autoimmune diseases, including acquired hypothyroidism 25 
(29). The extra X chromosome could predispose KS to higher prevalence of HT. Our Italian 26 
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national cohort results do not support this hypothesis and are in contrast with previous studies, in 1 
particular considering the prevalence of HT in our KS cohort.  This could be explained by the limits 2 
of a dataset from hospital discharge records and/or the diagnostic criteria of HT (28,29). 3 
Furthermore, a recent study based on data from the Danish National Patient Registry (10), analysed 4 
KS comorbidities, searching for differentially expressed genes in peripheral blood. There were 5 
genes causative of several Online Mendelian Inheritance in Man (OMIM) diseases such as 6 
‘abnormal thyroid hormone metabolism’, ‘epilepsy’ and ‘deafness’. These data indicate that more 7 
factors are involved in thyroid dysregulation in KS other than increased risk of autoimmune 8 
diseases. In previous studies, the most likely mechanism of thyroid abnormalities found in KS is an 9 
alteration in set point of thyrotrophic regulation of thyroid function (6-9). It is quite difficult to 10 
establish what are the causes and the effects of thyroid dysfunction in KS. However, we can exclude 11 
the influence of hypogonadism leading to a dysregulation of hypothalamic–pituitary–thyroid axis.  12 
In conclusion, our study indicates that KS present an impaired production of T4 by the thyroid 13 
gland, suggesting a different set point of the thyroid axis versus patients with hypogonadism due to 14 
other causes. No evidences of etiopathogenetic link to the hypogonadal status or change in set point 15 
of thyrotrophic control were found.  Further studies are needed to better understand the underlying 16 
mechanism(s) of thyroid dysregulation that may include evaluation of deiodinase activity, iodine 17 
intake and urinary iodine excretion.  18 
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or not-for-profit sector. 21 
22 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  10 
 1 
References 2 
1. Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA, Ferlin A; Klinefelter ItaliaN 3 
Group (KING) (2017) Klinefelter syndrome (KS): genetics, clinical phenotype and 4 
hypogonadism. J Endocrinol Invest 40:123-134  5 
2. Kanakis GA, Nieschlag E (2018) Klinefelter syndrome: more than hypogonadism. 6 
Metabolism 286:135-144 7 
3.  Calogero AE, Giagulli VA, Mongioì LM, Triggiani V, Radicioni AF, Jannini EA, Pasquali 8 
D; Klinefelter ItaliaN Group (KING) (2017) Klinefelter syndrome: cardiovascular 9 
abnormalities and metabolic disorders. J Endocrinol Invest 40:705-712 10 
4. Salzano A, Arcopinto M, Marra AM, et al (2016) Klinefelter syndrome, cardiovascular 11 
system, and thromboembolic disease: review of literature and clinical perspectives. Eur J 12 
Endocrinol 175:R27-40 13 
5. Di Minno MN, Esposito D, Di Minno A, et al (2015) Increased platelet reactivity in 14 
Klinefelter men: something new to consider. Andrology 3:876-878 15 
6. Smals AG, Kloppenborg PW, Lequin RL, Beex L, Ross A, Benraad TJ (1977) The pituitary-16 
thyroid axis in Klinefelter's syndrome. Acta Endocrinol (Copenh) 84:72-79 17 
7. Wortsman J, Moses HW, Dufau ML (1986) Increased incidence of thyroid disease among 18 
men with hypergonadotropic hypogonadism. Am J Med  80 1055-1059 19 
8.  Bjørn AM, Bojesen A, Gravholt CH, Laurberg PJ (2009) Hypothyroidism secondary to 20 
hypothalamic-pituitary dysfunction may be part of the phenotype in Klinefelter syndrome: a 21 
case-control study. J Clin Endocrinol Metab 94:2478-2481  22 
9. Tahani N, Ruga G, Granato S, et al (2017) A combined form of hypothyroidism in pubertal 23 
patients with non-mosaic Klinefelter syndrome. Endocrine 55:513-518            24 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  11 
10. Belling K, Russo F, Jensen AB, et al (2017) Klinefelter syndrome comorbidities linked to 1 
increased X chromosome gene dosage and altered protein interactome activity. Hum Mol 2 
Gen 26:1219–1229 3 
11. Jonklaas J, Bianco AC, Bauer AJ, et al (2014) American Thyroid Association Task Force on 4 
Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared 5 
by the American Thyroid Association task force on thyroid hormone replacement. Thyroid 6 
24: 1670-1751 7 
12. Ross DS, Burch HB, Cooper DS, et al (2016) American Thyroid Association Guidelines for 8 
diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 9 
26:1343-1421 10 
13. Aghini-Lombardi F, Antonangeli L, Martino E, et al (1999) The spectrum of thyroid 11 
disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol 12 
Metab 84 561–566  13 
14. Jostel A, Ryder WD, Shalet SM (2009) The use of thyroid function tests in the diagnosis of 14 
hypopituitarism: definition and evaluation of the TSH Index. Clin Endocrinol (Oxf) 71:529-15 
534  16 
15. Duarte-Guterman P, Navarro-Martín L, Trudeau VL (2014) Mechanisms of crosstalk 17 
between endocrine systems: regulation of sex steroid hormone synthesis and action by 18 
thyroid hormones. Gen Comp Endocrinol 203:69-85 19 
16. A. Wayne Meikle (2004) The Interrelationships Between Thyroid Dysfunction and 20 
Hypogonadism in Men and Boys. Thyroid 14 Suppl 1:S17-25 21 
17. De Felice M, Di Lauro R (2004) Thyroid development and its disorders: genetics and 22 
molecular mechanisms. Endocr Rev 25:722-746 23 
18. Carosa E, Lenzi A, Jannini EA (2018) Thyroid hormone receptors and ligands, tissue 24 
distribution and sexual behaviour. Mol Cell Endocrinol 467:49-59 25 
19. Vignozzi L, Corona G, Forti G; Jannini EA, Maggi M (2010) Clinical and therapeutic 26 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  12 
aspects of Klinefelter’s syndrome: sexual function. Mol Hum Reprod 16:418-424 1 
20. Pasquali D, Arcopinto M, Renzullo A, et al (2013) Cardiovascular abnormalities in 2 
Klinefelter syndrome. Int J Cardiol 168:754-759 3 
21. Groth KA, Skakkebæk A, Høst C, Gravholt CH, Bojesen A.J (2013) Clinical review: 4 
Klinefelter syndrome--a clinical update. J Clin Endocrinol Metab  98:20-30 5 
22. Salzano A, D'Assante R, Heaney LM, et al (2018) Klinefelter syndrome, insulin resistance, 6 
metabolic syndrome, and diabetes: review of literature and clinical perspectives. Endocrine 7 
61:194-203 8 
23. Park SY, Park SE, Jung SW, Jin HS, Park IB, Ahn SV, Lee S (2017) Free 9 
triiodothyronine/free thyroxine ratio rather than thyrotropin is more associated with 10 
metabolic parameters in healthy euthyroid adult subjects. Clin Endocrinol (Oxf)  87:87-96 11 
24. Aghini-Lombardi F, Antonangeli L, Martino E, et al (1999) J Clin Endocrinol Metab  12 
84:561–566  13 
25. McLeod DS, Cooper DS (2012) The incidence and prevalence of thyroid autoimmunity. 14 
Endocrine 42:252-265 15 
26. Zaletel K,and  Gaberšček S (2011) Hashimoto's Thyroiditis: From Genes to the Disease. 16 
Curr Genomics 12:576–588  17 
27. Brix TH, Knudsen GP, Kristiansen M, Kyvik KO, Orstavik KH, Hegedüs L (2005) High 18 
frequency of skewed X-chromosome inactivation in females with autoimmune thyroid 19 
disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin 20 
Endocrinol Metab 90:5949–5953 21 
28. Vallotton M, Forbes A (1967) Autoimmunity in gonadal dysgenesis and Klinefelter’s 22 
syndrome. Lancet 289:648–651 23 
29. Seminog OO, Seminog AB, Yeates D, Goldacre MJ (2015) Associations between 24 
Klinefelter's syndrome and autoimmune diseases: English national record linkage studies. 25 
Autoimmunity 48:125-128 26 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
  13 
Legends to figures 1 
Figure 1. FT4 levels in Klinefelter syndrome vs. non-Klinefelter syndrome  2 
Figure 2. FT3/FT4 ratio in Klinefelter syndrome vs. non-Klinefelter syndrome. Data are expressed 3 
as mean ± SD  4 
Figure 3. TSH index in Klinefelter syndrome vs. non-Klinefelter syndrome. Data are expressed as 5 
Mean ± SD.  6 
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Figure Click here to access/download;Figure;Diapositiva3.tiff
 Table 1. Clinical, demographical and hormonal data of subjects with Klinefelter syndrome 
(KS) or with hypogonadism due to other causes (non-KS).  
 
  KS non-KS p 
Number of patients 174 62  
Hashimoto’s thyroiditis 
(prevalence) 
7% 4%  
Age (years) 40.6 ± 1.1 40.0 ± 2.4 ns 
Testosterone (ng/dl) 324.3 ± 69 284.7 ± 36.5 0.05 
TSH (IU/L) 1.83 ± 0.1 2.02 ± 0.1 ns 
FT3 (pmol/L) 3.3± 0.8 3.2 ±0.1 ns 
FT4 (pmol/L) 10.6 ± 0.3 11.7 ± 0.4 < 0.006 
Data are reported as mean ± SD; ns= Not significant 
Table Click here to access/download;Table;Table 1.doc
 Table 2. Diagnoses of patients with hypogonadism not due to Klinefelter syndrome (control 
group) 
 Number of cases 
Kallmann syndrome 33 
After pituitary surgery 8 
Idiopathic 17 
Iatrogenic 4 
Total 62 
  
Table Click here to access/download;Table;Table 2.doc
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